





From Evidence to Implementation: Key priorities for pharmacogenomics-guided treatment and prevention from a European expert workshop

Loes Lindiwe Kreeftenberg, Lidewij Henneman, Tessel Rigter, Department of Human Genetics, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands & Amsterdam Public Health Research Institute, Amsterdam, the Netherlands; **Angelica Valz Gris**, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy; **Adrián LLerena**, INUBE Extremadura Biosanitary Research Institute, Unit of Pharmacogenetics and Personalized Medicine, Badajoz University Hospital, Spain; **John H McDermott**, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK & The Division of Evolution, Infection and Genomics, School of Biological Sciences, University of Manchester, Manchester, UK; **Maureen Rutten-van Mölken**, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; **Astrid Moura Vicente**, Department of Health Promotion and NCD Prevention, Instituto nacional de saúde doutor ricardo jorge, Lisbon, Portugal; **Ron H.N. van Schaik**, Department of Clinical Chemistry, Erasmus MC – University Medical Center, Rotterdam, The Netherlands; **Videha Sharma**, Centre for Health Informatics, Division of Informatics, Imaging and Data Science, University of Manchester Faculty of Biology, Medicine and Health, Manchester, Greater Manchester, UK; **Jesse J. Swen**, Leiden University Medical Center, Department of Clinical Pharmacy & Toxicology, The Netherlands; **Martina C. Cornel, Carla G. van El**

Why Pharmacogenomics Matters

-  Enhance drug safety and efficacy
→ Reduce adverse drug reactions and adjust and optimise medication or dosage
-  Support personalised medicine
-  Enable patient-centred healthcare

Pillars of Implementation



Workshop & Analysis Approach

- European Multistakeholder Expert Workshop, Amsterdam, Jan 2025
- 55 participants, 14 speakers, 10 countries
- Representation from policy, healthcare, academia, patients, industry etc.
- A qualitative content analyses was conducted



Towards Pharmacogenomics Implementation in Public Health

- Move from innovation to standard practise across Europe
- Need for more alignment, via e.g., a coordinating network to lead, align, and scale initiatives across Europe
- Multidisciplinary collaboration is needed across research, care, and governance
- Implementation requires progress across the 3 pillars

Pillars of implementation	Key priorities	Examples of actions
1 Evidence	Need for robust clinical & health economic evaluations to support funding and reimbursement decisions	<ul style="list-style-type: none"> • <i>Generate robust, policy-relevant evidence on both clinical utility and cost-effectiveness</i> • <i>Inclusion of diverse populations to capture PGx variation (ethnicity)</i> • <i>Identify patient groups who benefit most to optimise resource allocation</i>
2 Acceptance	Education and training for healthcare professionals & raising policymakers & public awareness of pharmacogenomic	<ul style="list-style-type: none"> • <i>Train healthcare professionals when to apply & how to interpret PGx tests</i> • <i>Raise public awareness via campaigns and digital tools</i> • <i>Engage policymakers align regulatory, reimbursement, & demonstrate clinical and economic value of PGx</i>
3 Integration	Investment in IT infrastructure for interoperable storage and clinical decision making	<ul style="list-style-type: none"> • <i>Integrate PGx data in electronic health records & clinical decision support systems</i> • <i>Facilitate availability of test results at point of care throughout the healthcare chain from general practice to tertiary care</i>
4	Harmonising regulatory and reimbursement policies	<ul style="list-style-type: none"> • <i>Defining reimbursement models</i> • <i>Aligning EU and national (regulatory) policies</i>
5	Ensuring equitable access	<ul style="list-style-type: none"> • <i>Reduce financial & geographic barriers</i> • <i>Tailor national strategies & promote data integration</i>

